Pioglitazon: Perbedaan antara revisi

Pioglitazon digunakan untuk menurunkan kadar glukosa darah pada [[Diabetes melitus tipe 2|diabetes tipe 2]] baik dalam pemberian tunggal atau dalam kombinasi dengan [[ Sulfonylurea|sulfonilurea]], [[ Pioglitazone / metformin|metformin]], atau [[insulin]].<ref name="Actos Label">{{Cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c|title=Actos- pioglitazone tablet|date=25 January 2019|website=DailyMed|access-date=13 February 2020}}</ref> Pioglitazon memang menurunkan kadar gula darah, tetapi penelitian yang utamanya melihat pada luaran kardiovaskular, obat ini tidak memberikan perbedaan hasil.<ref name="Scheen2012">{{Cite journal|date=November 2012|title=Outcomes and lessons from the PROactive study|url=http://orbi.ulg.ac.be/jspui/handle/2268/132794|journal=Diabetes Research and Clinical Practice|volume=98|issue=2|pages=175–86|doi=10.1016/j.diabres.2012.09.001|pmid=23020930|quote=Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.|vauthors=Scheen AJ|access-date=2020-05-23|archive-date=2021-01-28|archive-url=https://web.archive.org/web/20210128055222/https://orbi.uliege.be//handle/2268/132794|dead-url=yes}}</ref> Hasil sekunder kematian dari semua penyebab, infark miokard, dan stroke adalah lebih rendah.<ref name="Scheen2012" />